NEW YORK (GenomeWeb News) – Diagnostics developer Tethys Bioscience said today that it has bought Lipomics Technologies, a metabolite-profiling firm, for an undisclosed sum.
Tethys, which earlier this year began selling a test for diabetes risk, said the acquisition will help it to develop new tests to predict the likelihood of developing chronic diseases. Currently, Emeryville, Calif.-based Tethys is developing a test to predict the likelihood that a person will experience osteoporotic bone fracture or a major cardiac event.
All of Lipomics’ 30 employees will become part of Tethys, and Lipomics’ Co-founder and Chief Scientific Officer Steven Watkins will become Tethys’ chief technology officer.
Lipomics’ facility will continue handling quantitative lipid metabolite profiling as Tethys West Sacramento.